Current and Emerging Biologics for Atopic Dermatitis.

Humans Dermatitis, Atopic / drug therapy Biological Products / therapeutic use Antibodies, Monoclonal / therapeutic use Cytokines / metabolism Animals Antibodies, Monoclonal, Humanized / therapeutic use
Atopic dermatitis Biologics Dupilumab Eczema Lebrikizumab Monoclonal antibody Nemolizumab Tralokinumab

Journal

Immunology and allergy clinics of North America
ISSN: 1557-8607
Titre abrégé: Immunol Allergy Clin North Am
Pays: United States
ID NLM: 8805635

Informations de publication

Date de publication:
Nov 2024
Historique:
medline: 11 10 2024
pubmed: 11 10 2024
entrez: 10 10 2024
Statut: ppublish

Résumé

Atopic dermatitis (AD) is a common chronic pruritic inflammatory skin disease that affects all ages and is recognized as a global health problem. Pathophysiology is complex with skin barrier abnormalities, immune dysregulation, and microbial dysbiosis all implicated. Markers of immune and inflammatory activation in the circulation provide a rationale for systemic therapy. Type 2 immune polarization is central, though other cytokine pathways including Th22 and Th17/IL-23 have been described, suggesting additional therapeutic targets in a subset of patients. Dupilumab and tralokinumab are monoclonal antibodies currently approved for moderate-to-severe AD with lebrikizumab and nemolizumab in late stages of development.

Identifiants

DOI: 10.1016/j.iac.2024.08.001 PMID: 39389711
pubmed: 39389711
pii: S0889-8561(24)00058-4
doi: 10.1016/j.iac.2024.08.001
pii:
doi:

Substances chimiques

Biological Products 0
Antibodies, Monoclonal 0
Cytokines 0
Antibodies, Monoclonal, Humanized 0
dupilumab 420K487FSG

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

577-594

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure M. Nevid has no conflicts to disclose. M. Boguniewicz has been involved in clinical research for Regeneron and Sanofi-Genzyme and served as a consultant for Amgen, Eli Lilly, LEO Pharma, Regeneron, and Sanofi-Genzyme.

Auteurs

Michael Nevid (M)

Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, 1400 Jackson Street, J312, Denver, CO 80206, USA.

Mark Boguniewicz (M)

Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, 1400 Jackson Street, J310, Denver, CO 80206, USA. Electronic address: boguniewiczm@njhealth.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Current and Emerging Biologics for Atopic Dermatitis.
questionsmedicales.fr › Maladies du système immunitaire › Hypersensibilité › Hypersensibilité immédiate › Eczéma atopique › Current and Emerging Biologics for Atopic Dermatitis.
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Current and Emerging Biologics for Atopic Dermatitis.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Current and Emerging Biologics for Atopic Dermatitis.
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Current and Emerging Biologics for Atopic Dermatitis.
questionsmedicales.fr › Eucaryotes › Animaux › Current and Emerging Biologics for Atopic Dermatitis.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Current and Emerging Biologics for Atopic Dermatitis.